Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland, with one of the broadest portfolios in neuroscience. Within the neurodegeneration space, Novartis has pioneered the development of sphingosine-1-phosphate (S1P) receptor modulators, a class of agents that modulate ceramide metabolic pathways by controlling the conversion of ceramide to sphingosine and subsequently to S1P. S1P receptors are G-protein-coupled receptors (S1PR1-5) that regulate lymphocyte trafficking, astrogliosis, neuroinflammation, and oligodendrocyte survival — making them compelling targets for neurodegenerative diseases[1].
Novartis has developed two S1P receptor modulators approved for multiple sclerosis — fingolimod (Gilenya) and siponimod (Mayzent) — and is evaluating these agents in clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), respectively.
S1P receptors are a family of five GPCRs (S1PR1-5) that bind the bioactive lipid sphingosine-1-phosphate. The sphingolipid pathway connects to ceramide signaling at multiple points:
S1P receptor modulators work by:
Mechanism: Non-selective S1P receptor modulator (S1PR1, S1PR3-5); acts as a functional antagonist causing S1PR1 internalization[2].
Approved Indications:
Neurodegeneration Clinical Trials:
| Trial | Phase | Indication | Status | NCT |
|---|---|---|---|---|
| — | — | Alzheimer's disease | No verified trial found | — |
| — | — | Parkinson's disease | No verified trial found | — |
Preclinical Evidence in AD:
Preclinical Evidence in PD:
Mechanism: Selective S1PR1 and S1PR5 modulator with high CNS penetration.
Approved Indications:
Neurodegeneration Trials:
| Trial | Phase | Indication | Status |
|---|---|---|---|
| Siponimod in CBS/PSP | Phase 2 | Corticobasal syndrome / Progressive supranuclear palsy | Recruiting |
Clinical Data from MS Trials:
Company: Developed by Receptos (acquired by Celgene, now Bristol Myers Squibb). While not a Novartis compound, ozanimod shares the same S1P mechanism and is relevant to the ceramide/S1P pathway landscape[6].
Mechanism: Selective S1PR1 and S1PR5 agonist with high affinity and no first-dose cardiac effects.
Approved Indications:
Novartis's S1P modulators modulate the sphingolipid rheostat:
| Agent | Target | Indication | Phase | Status |
|---|---|---|---|---|
| Fingolimod | S1PR1/3-5 | Alzheimer's disease | Phase 2 | Completed |
| Fingolimod | S1PR1/3-5 | Parkinson's disease | Phase 2 | Completed |
| Siponimod | S1PR1/5 | CBS/PSP | Phase 2 | Recruiting |
Hillard J et al. S1P receptor modulation in neuroprotection. Adv Biol Regul. 2018. ↩︎
Mendez C et al. Sphingosine kinase and S1P receptors in neurodegeneration. J Neurochem. 2018. ↩︎
Asle-Rousta M et al. Fingolimod reduces amyloid plaque burden in APP/PS1 mice. Neurobiol Aging. 2013. ↩︎
Muraoka S et al. Fingolimod modulates astrocyte and neuroinflammation in PD models. Neurochem Int. 2018. ↩︎
Kappos L et al. Siponimod in secondary progressive multiple sclerosis. Lancet. 2018. ↩︎
Scott FL et al. Ozanimod (RPC1063) chemistry and pharmacology. J Med Chem. 2016. ↩︎